A Study of Ovarian Cancer Patients Treated with Dose-intensive Chemotherapy Supported with Peripheral Blood Progenitor Cells Mobilised by Filgrastim and Cyclophosphamide

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Dec 1

PMID 8956800

Authors

A Weaver

E Wrigley

A Watson

J Chang

C D Collins

B Jenkins

C Gill

R Pettengell

T M Dexter

N G Testa

D Crowther

Affiliations

Soon will be listed here.

Abstract

We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone (10 micrograms kg-1), the apheresis harvest contained a median CFU-GM count of 45 x 10(4) kg-1 and 2 x 10(6) kg-1 CD34+ cells. Treatment with filgrastim (5 micrograms kg-1) following cyclophosphamide (3 g m-2) resulted in a harvest containing 66 x 10(4) kg-1 CFU-GM and 2.4 x 10(6) kg-1 CD34+ cells. There was no statistically significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide (900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval between treatment cycles to 2 weeks. However, at this dose intensity less than a third of patients received their planned treatment on time. All the delays were due to thrombocytopenia.

References

Levin L, Hryniuk W . Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987; 5(5):756-67. DOI: 10.1200/JCO.1987.5.5.756. View

Parkin D, Laara E, Muir C . Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988; 41(2):184-97. DOI: 10.1002/ijc.2910410205. View

Socinski M, Cannistra S, Elias A, Antman K, Schnipper L, Griffin J . Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988; 1(8596):1194-8. DOI: 10.1016/s0140-6736(88)92012-0. View

Hryniuk W . The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988; :121-41. View

Duhrsen U, Villeval J, Boyd J, Kannourakis G, Morstyn G, Metcalf D . Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988; 72(6):2074-81. View

Ngan H, Choo Y, Cheung M, Wong L, Ma H, Collins R . A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy. 1989; 35(3):221-7. DOI: 10.1159/000238673. View

Feremans W, Le Moine F, Ravoet C, Lambermont M, Bastin G, Delville J . Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am J Hematol. 1994; 47(2):135-8. DOI: 10.1002/ajh.2830470214. View

Calvert A, Newell D, Gumbrell L, OReilly S, Burnell M, Boxall F . Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7(11):1748-56. DOI: 10.1200/JCO.1989.7.11.1748. View

Siena S, Bregni M, Brando B, BELLI N, Ravagnani F, Gandola L . Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood. 1991; 77(2):400-9. View

10.

Kaye S, Lewis C, Paul J, Duncan I, Gordon H, Kitchener H . Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992; 340(8815):329-33. DOI: 10.1016/0140-6736(92)91404-v. View

11.

Andrews R, Bartelmez S, Knitter G, Myerson D, Bernstein I, Appelbaum F . A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. Blood. 1992; 80(4):920-7. View

12.

Russell N, Hunter A, Rogers S, Hanley J, Anderson D . Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet. 1993; 341(8858):1482. DOI: 10.1016/0140-6736(93)90929-b. View

13.

Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M . A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol. 1993; 4(5):377-83. DOI: 10.1093/oxfordjournals.annonc.a058516. View

14.

Gianni A, Siena S, Bregni M, Tarella C, Stern A, Pileri A . Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989; 2(8663):580-5. DOI: 10.1016/s0140-6736(89)90711-3. View